01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsNextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNextCell in the mediaEventsCompany PresentationsQ&A with CEO
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell – Part of the Stem Cell Revolution

Stem and stromal cells are expected to revolutionize the treatment of today’s severe and incurable diseases. NextCell develops pioneering stromal cell therapies for the treatment of autoimmune and inflammatory diseases. NextCell's drug candidate, ProTrans, is at the forefront of our development for the treatment of type 1 diabetes.

NextCell's Product Portfolio

NextCell develops novel stromal cell therapies, with a primary focus on type 1 diabetes. The lead candidate ProTrans, is based on NextCell patented selection algorithm. NextCell also runs Cellaviva, Scandinavia's largest private stem cell bank.
Read more

About NextCell

NextCell is a Swedish biopharmaceutical company operating in three business areas – Cellaviva, ProTrans and QVance – with the shared core being cell therapies and development of advanced therapy medicinal products (ATMPs).
Sample in a lab is being examinedRead more

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.
Read more
Cover art of NextCell report
Read our latest report:
Interim Report Q2 2026
Download

News

2026-08-27

Interim Report second quarter 2026

Regulatory
NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the second quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year.  Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.
Read moreRead more
2026-08-18

NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong

Regulatory
NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.
Read moreRead more
2026-05-28

Interim Report first quarter 2026

Regulatory
NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the first quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year.  Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.
Read moreRead more
2026-05-27

NextCell Pharma AB (publ) Annual General Meeting 2026

Regulatory
On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 (“NextCell” or the “Company”), was held. A summary of the resolutions adopted at the Annual General Meeting is set out below. All resolutions were adopted with the required majority. For more detailed information regarding the content of the resolutions, reference is made to the notice convening the Annual General Meeting and the complete proposals for resolutions, which have previously been published and are available on the Company’s website, www.nextcellpharma.com.
Read moreRead more
All news

Subscribe to press releases

By filling out the form you are approving that NextCell Pharma stores your information. Read more about our integrity policy here.
I am not a robot.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please try again.
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept